News und Analysen

The past five years have been challenging for Bristol Myers Squibb (NYSE: BMY). The company lost patent exclusivity for some key products, including one that was once its best-selling medicine

Shares of Praxis Precision Medicines (NASDAQ: PRAX) leaped on Monday after the clinical-stage biopharmaceutical company received a Breakthrough Therapy Designation (BTD) for its experimental tremor

Heading into 2026 on an inauspicious note, Ultragenyx Pharmaceuticals (NASDAQ: RARE), a pharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases, announced

Intellia Therapeutics (NASDAQ: NTLA) and Iovance Biotherapeutics (NASDAQ: IOVA) are relatively innovative biotech companies. However, due to company-specific headwinds, both have seen their shares

On a planet whose surface consists mostly of water, it's not a surprise to see different companies cashing in on transporting guests across the many oceans, seas, and rivers. Carnival Corp. (NYSE:

Oregon-based Stonepine Capital Management reported a sale of 250,000 shares of Indivior PLC (NASDAQ:INDV), reducing its position by approximately $2.75 million, according to a November 13 SEC

The pharmaceutical industry is highly technical, and significant developments can rapidly transform the sector. For instance, Novo Nordisk's (NYSE: NVO) introduction of GLP-1 weight loss drugs was a

While the healthcare sector has not kept pace with broader equities so far, some industry leaders have. AbbVie (NYSE: ABBV), a pharmaceutical giant, is one of them. The company's shares are up by

Rigetti Computing (NASDAQ: RGTI) was one of the hottest quantum computing stocks in 2025, as the company hit some important hardware milestones this year. This included demonstrating the industry's

On Dec. 17, 2025, Michael Castagna, Chief Executive Officer of MannKind Corporation (NASDAQ:MNKD), executed an exercise and immediate sale of 65,804 common shares for a transaction value of

For the most part, the stock market tends to be sedate in the late holiday season. That sure wasn't the case on Wednesday with Omeros (NASDAQ: OMER), which saw a nearly 76% share price leap after

Shares of Dynavax Technologies (NASDAQ: DVAX) popped on Wednesday after the vaccine maker struck a deal to be acquired by Sanofi (NASDAQ: SNY).

As of 3:00 p.m. EST, Dynavax's stock price was up

On November 13, New York City-based Hyperion Capital Advisors disclosed a new position in Vertex (NASDAQ:VERX), acquiring 540,000 shares valued at approximately $13.39 million.

According to a filing

Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME

Novo Nordisk (NYSE:NVO), which develops and markets diabetes and obesity treatments, closed Tuesday’s session at $51.61, up 7.30% after U.S. approval of its once-daily oral Wegovy weight-loss pill

New York City-based Horizon Kinetics Asset Management disclosed a new position in WaterBridge Infrastructure LLC (NYSE:WBI), acquiring about 6.35 million shares valued at $160.26 million, per a

New York City-based Horizon Kinetics Asset Management reported a buy of 133,188 shares of LandBridge Company LLC (LB), while the position value decreased by $71.14 million, per a November 14 SEC

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and other AI stocks. To learn more, check out the short video, consider subscribing,

Shares of Novo Nordisk (NYSE: NVO) surged after the company introduced its GLP-1 weight loss drugs to the market. Investors correctly recognized the desirability of a weight loss drug, but, as often

A decade ago, Advanced Micro Devices (NASDAQ: AMD) was in a difficult position. Revenue fell 28% in 2015, primarily due to declining processor sales, and the company posted a net loss of $660

Pfizer (NYSE: PFE) and Merck (NYSE: MRK) are two pharmaceutical giants that have lagged broader equities this year. Both have delivered unimpressive financial results recently, and are facing a

B. Lynne Parshall, Director at Cytokinetics, Incorporated (NASDAQ:CYTK), reported the sale of 5,000 shares in an open-market transaction valued at ~$323,650 on November 19, 2025; direct ownership

CRISPR Therapeutics (NASDAQ: CRSP) has had a volatile performance over the past five years. While its stock is up more than 40% this year, in three of the past five years it has fallen by more than

Valuations for many stocks are sky-high, and that can make now an unappealing time to invest in the stock market. However, there are still some great value buys that don't involve taking on a lot of